



Calmark presents at Redeye Life Science Day 2021

Calmark attends the digital event Redeye Life Science Day 2021 that will be held on November 11. CEO Anna Söderlund presents the latest developments and the future prospects for the company at 11:20. The presentation is held in Swedish and will be broadcast live.

Redeye's Life Science Day on November 11 will again be held digitally and provides space to ask questions and have in-depth discussions about the invited companies and their respective areas.

The event takes place between 8:30 - 17:00 in three different streams. Two streams of company presentations followed by a Q&A session with Redeye analysts. The third stream, Redeye TV, will send On-site presentations, Investment Cases and will also focus on in-depth interviews and debates.

In total, about 50 companies will present during the day. Everything will be recorded and broadcast live.

Read more and register at:

<https://www.redeye.se/events/815899/redeye-life-science-day-2021>

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.